Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab
In this real-world diverse population, we observed rates of irAEs comparable with KEYNOTE-522, where endocrinopathies were the most prevalent, but GI irAEs were also prevalent and severe. This emphasizes a critical issue as pembrolizumab is increasingly being used in early TNBC and could have long-term survivorship implications.
Authors
- Athira Jayan (ORCID: https://orcid.org/0000-0001-8926-3306)
- Sonya Khan (ORCID: https://orcid.org/0009-0009-4456-6739)
- Akshara Singareeka Raghavendra (ORCID: https://orcid.org/0000-0002-6425-4400)
- Benjamin David Fangman (ORCID: https://orcid.org/0000-0003-2437-0738)
- Tejal Patel (ORCID: https://orcid.org/0000-0003-1676-8439)
- Carlos H. Bárcenas (ORCID: https://orcid.org/0000-0001-5377-9167)
- Jasmine Sukumar (ORCID: https://orcid.org/0000-0001-6994-8527)
- Karen Basen‐Engquist (ORCID: https://orcid.org/0000-0001-7299-0646)
- Diane D. Liu (ORCID: https://orcid.org/0000-0003-3301-0259)
- Sarah Pasyar
- Yinghong Wang (ORCID: https://orcid.org/0000-0002-5148-6130)
- Ronald A. Rauch
- Debasish Tripathy
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1200/op.24.00371
- Citations
- 15
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.24
Funders
- University of Texas MD Anderson Cancer Center